New Contracts and Products Help Emergent BioSolutions Inc Get It Done

New Contracts and Products Help Emergent BioSolutions Inc Get It Done

Emergent BioSolutions (NYSE: EBS) continues toward its goal of having $1 billion in revenue in 2020 with a solid third-quarter performance that exceeded its own guidance of revenue in the range of $115 million to $130 million.

Metric

Q3 2017

Continue reading

Source: Fool.com